BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 32037739)

  • 1. The rapidly advancing Class 2 CRISPR-Cas technologies: A customizable toolbox for molecular manipulations.
    Wang J; Zhang C; Feng B
    J Cell Mol Med; 2020 Mar; 24(6):3256-3270. PubMed ID: 32037739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and Repurposing of Type I and Type II CRISPR-Cas Systems in Bacteria.
    Hidalgo-Cantabrana C; Goh YJ; Barrangou R
    J Mol Biol; 2019 Jan; 431(1):21-33. PubMed ID: 30261168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type III CRISPR-Cas System: Introduction And Its Application for Genetic Manipulations.
    Liu T; Pan S; Li Y; Peng N; She Q
    Curr Issues Mol Biol; 2018; 26():1-14. PubMed ID: 28879852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlling and enhancing CRISPR systems.
    Shivram H; Cress BF; Knott GJ; Doudna JA
    Nat Chem Biol; 2021 Jan; 17(1):10-19. PubMed ID: 33328654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A detailed cell-free transcription-translation-based assay to decipher CRISPR protospacer-adjacent motifs.
    Maxwell CS; Jacobsen T; Marshall R; Noireaux V; Beisel CL
    Methods; 2018 Jul; 143():48-57. PubMed ID: 29486239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. History of CRISPR-Cas from Encounter with a Mysterious Repeated Sequence to Genome Editing Technology.
    Ishino Y; Krupovic M; Forterre P
    J Bacteriol; 2018 Apr; 200(7):. PubMed ID: 29358495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Based Technologies: Impact of RNA-Targeting Systems.
    Terns MP
    Mol Cell; 2018 Nov; 72(3):404-412. PubMed ID: 30388409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shooting the messenger: RNA-targetting CRISPR-Cas systems.
    Zhu Y; Klompe SE; Vlot M; van der Oost J; Staals RHJ
    Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29748239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Revolution Continues: Newly Discovered Systems Expand the CRISPR-Cas Toolkit.
    Murugan K; Babu K; Sundaresan R; Rajan R; Sashital DG
    Mol Cell; 2017 Oct; 68(1):15-25. PubMed ID: 28985502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CRISPR proteins targeting the CRISPR-Cas system enrich the toolkit for genetic engineering.
    Liu Q; Zhang H; Huang X
    FEBS J; 2020 Feb; 287(4):626-644. PubMed ID: 31730297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type II anti-CRISPR proteins as a new tool for synthetic biology.
    Zhang Y; Marchisio MA
    RNA Biol; 2021 Aug; 18(8):1085-1098. PubMed ID: 32991234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of Microbial Diversity to Discover Novel Molecular Technologies.
    Zhang F
    Keio J Med; 2019; 68(1):26. PubMed ID: 30905885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finally, Archaea Get Their CRISPR-Cas Toolbox.
    Gophna U; Allers T; Marchfelder A
    Trends Microbiol; 2017 Jun; 25(6):430-432. PubMed ID: 28391963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR-Cas systems: ushering in the new genome editing era.
    Perez Rojo F; Nyman RKM; Johnson AAT; Navarro MP; Ryan MH; Erskine W; Kaur P
    Bioengineered; 2018; 9(1):214-221. PubMed ID: 29968520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editor's cut: DNA cleavage by CRISPR RNA-guided nucleases Cas9 and Cas12a.
    Swartjes T; Staals RHJ; van der Oost J
    Biochem Soc Trans; 2020 Feb; 48(1):207-219. PubMed ID: 31872209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and applications of Type I CRISPR-Cas systems.
    Hidalgo-Cantabrana C; Barrangou R
    Biochem Soc Trans; 2020 Feb; 48(1):15-23. PubMed ID: 31922192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid Control of Genome Editing in Human Cells by Chemical-Inducible CRISPR-Cas Systems.
    Liu KI; Ramli MNB; Sutrisnoh NB; Tan MH
    Methods Mol Biol; 2018; 1772():267-288. PubMed ID: 29754234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Genome Editing and its Potential Enhancement through CRISPR Guide RNA and Cas9 Modifications.
    Batzir NA; Tovin A; Hendel A
    Pediatr Endocrinol Rev; 2017 Jun; 14(4):353-363. PubMed ID: 28613045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CRISPR/CAS9, the King of Genome Editing Tools].
    Bannikov AV; Lavrov AV
    Mol Biol (Mosk); 2017; 51(4):582-594. PubMed ID: 28900076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-Cas9-Mediated Genome Editing and Transcriptional Control in Yarrowia lipolytica.
    Schwartz C; Wheeldon I
    Methods Mol Biol; 2018; 1772():327-345. PubMed ID: 29754237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.